← Leaderboards
Ranajit Pal
Advanced Bioscience Laboratories, Inc.
$45,474,422
Attributed
$45,474,422
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $10.3M · FY2011–24$20M$15M$10M$5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$45,474,422 · 3
By mechanism
N01$45,474,422 · 3
Top collaborators
No co-investigators on record.
Most similar at Advanced Bioscience Laboratories, Inc.
Same institution · by research overlap
- Peter Silvera$18,392,128
- Maria Grazia Ferrari$2,400,205
- Glenn Swartz$1,044,520
- Glen Swartz$1,137,319
- Pal Ranajit$4,929,175
Others in their field
Top investigators on “National Institute Of Allergy And Infectious Disease”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$271,371,465
- Barbara Driver · Westat, Inc.$223,674,652
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$203,912,871
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
National Institute Of Allergy And Infectious DiseasePre-ClinicalPreventionResourcesContractsPrevention StrategyNonhuman PrimateAids VaccinesVaccine EvaluationResearch PersonnelInvestigator-Initiated ResearchModalityProgramsAdvanced DevelopmentLocal MicrobicidesComplementGrantHiv VaccinePreclinical EvaluationEvaluation StudiesPreclinical StudyAwardFundingVaccine Candidate
Grant awards (74)
Conduct Study P193: Evaluation of Immune Responses after Priming with Newcastle Disease Virus and Boosting with Trimeric gp145 Proteins from Indian and African Clade C HIV-1 Isolates$114,158
N01 · FY2024 · AI · contact PI
Evaluation of the Immunogenicity and Efficacy of HIV-1 Clade A BG505 SOSIP.664 Env Glycoprotein Trimer Vaccine Administered with TLR Agonist or Alum Adjuvants$11,916
N01 · FY2024 · AI · contact PI
Comprehensive Resources for HIV Microbicides and Biomedical Prevention: Quality Assurance/ Quality Control (QA/QC)$20,044
N01 · FY2023 · AI · contact PI
Simian Vaccine Evaluation Unit - Operations of a Nonhuman Primate Breeding Colony$17,651
N01 · FY2023 · AI · contact PI
EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF HIV-1 CLADE C OLIGOMERIC ENVELOPE PROTEIN DELIVERED WITH ADVAX DELTA INULIN ADJUVANT BY INTRAMUSCULAR AND INTRAPULMONARY ROUTES$3,365
N01 · FY2023 · AI · contact PI
Simian Vaccine Evaluation Unit - Operations of a Nonhuman Primate Breeding Colony$110,474
N01 · FY2022 · AI · contact PI
Evaluation of the Immunogenicity and Efficacy of a DNA Prime/Protein Boost Vaccine$2,799
N01 · FY2022 · AI · contact PI
Comprehensive Resources for HIV Microbicides and Biomedical Prevention: NHP Purchase and Holding$934,848
N01 · FY2020 · AI · contact PI
Comparison of Bivalent vs Pentavalent Subtype C Envelope HIV-1 Vaccine Efficacy Following Mucosal Virus Challenge$604,528
N01 · FY2020 · AI · contact PI
Evaluation of the Immunogenicity and Efficacy of a DNA Prime/Protein Boost Vaccine$331,449
N01 · FY2020 · AI · contact PI
PRECLINICAL GAP-FILLING SERVICES: STUDIES TO ASSESS INTERACTIONS BETWEEN DAPIVIRINE AND VAGINALLY-APPLIED, OVER-THE-COUNTER PRODUCTS$229,002
N01 · FY2020 · AI · contact PI
SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY$2,371,101
N01 · FY2019 · AI · contact PI
Comprehensive Resources for HIV Microbicides and Biomedical Prevention: NHP Purchase and Holding$918,721
N01 · FY2019 · AI · contact PI
Evaluation of the Immunogenicity and Efficacy of HIV-1 Clade A BG505 SOSIP.664 Env Glycoprotein Trimer Vaccine Administered with TLR Agonist or Alum Adjuvants$883,231
N01 · FY2019 · AI · contact PI
SVEU - MAINTENANCE OF NONHUMAN PRIMATES$322,170
N01 · FY2019 · AI · contact PI
STATISTICAL AND PHARMACOMETRIC MODELING SUPPORT FOR HIV NON-VACCINE BIOMEDICAL PREVENTION PRODUCT DEVELOPMENT$253,935
N01 · FY2019 · AI · contact PI
Evaluation of Immune Responses to a Trimerically Stabilized gp120 Immunogen$234,879
N01 · FY2019 · AI · contact PI
Conduct Study P193: Evaluation of Immune Responses after Priming with Newcastle Disease Virus and Boosting with Trimeric gp145 Proteins from Indian and African Clade C HIV-1 Isolates$165,968
N01 · FY2019 · AI · contact PI
Comparison of Bivalent vs Pentavalent Subtype C Envelope HIV-1 Vaccine Efficacy Following Mucosal Virus Challenge$155,219
N01 · FY2019 · AI · contact PI
Ethnographic Expertise for Enhancing Study Drug Adherence in HIV Prevention Trials$138,847
N01 · FY2019 · AI · contact PI
SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY$2,268,617
N01 · FY2018 · AI · contact PI
EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF HIV-1 CLADE C OLIGOMERIC ENVELOPE PROTEIN DELIVERED WITH ADVAX DELTA INULIN ADJUVANT BY INTRAMUSCULAR AND INTRAPULMONARY ROUTES$2,041,729
N01 · FY2018 · AI · contact PI
Evaluation of the Immunogenicity and Efficacy of a MVA-HIV Prime, gp145 HIV protein/ALFA-adjuvanted Boost Vaccine Regimen with SHIV-CH505 Challenge in Male Rhesus Macaques$941,082
N01 · FY2018 · AI · contact PI
PRECLINICAL GAP-FILLING SERVICES: STUDIES TO ASSESS INTERACTIONS BETWEEN DAPIVIRINE AND VAGINALLY-APPLIED, OVER-THE-COUNTER PRODUCTS$919,179
N01 · FY2018 · AI · contact PI
NONHUMAN PRIMATE PURCHASE AND HOLDING$897,758
N01 · FY2018 · AI · contact PI
Comprehensive Resources for HIV Microbicides and Biomedical Prevention: Quality Assurance/ Quality Control (QA/QC)$790,559
N01 · FY2018 · AI · contact PI
CHARACTERIZATION OF THE PHARMACOKINETIC PROFILE OF A CANDIDATE HIV PREVENTION DRUG IN RHESUS MACAQUES$758,066
N01 · FY2018 · AI · contact PI
Statistical Support for HIV Non-vaccine Biomedical Prevention Product Development$406,921
N01 · FY2018 · AI · contact PI
EXPANSION AND CHARACTERIZATION OF RELEVANT SIMIAN IMMUNODEFICIENCY VIRUS (SIV) STOCKS FOR USE IN DRUG ASSAYS OR REPEAT, LOW-DOSE CHALLENGE STUDIES IN RHESUS MACAQUES$359,937
N01 · FY2018 · AI · contact PI
SIMIAN VACCINE EVALUATION UNITS: Comparison of Bivalent vs Pentavalent Subtype C Envelope HIV-1 Vaccine Efficacy$355,415
N01 · FY2018 · AI · contact PI
SVEU - MAINTENANCE OF NONHUMAN PRIMATES$314,498
N01 · FY2018 · AI · contact PI
SIMIAN VACCINE EVALUATION UNITS: Virus In Vivo Titration Study$140,441
N01 · FY2018 · AI · contact PI
Ethnographic Expertise for Enhancing Study Drug Adherence in HIV Prevention Trials$135,374
N01 · FY2018 · AI · contact PI
SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY$2,265,914
N01 · FY2017 · AI · contact PI
NONHUMAN PRIMATE PURCHASE AND HOLDING$1,657,672
N01 · FY2017 · AI · contact PI
QUALITY ASSURANCE/ QUALITY CONTROL (QA/QC)$763,839
N01 · FY2017 · AI · contact PI
NONHUMAN PRIMATE CORE QUANT IRAL RNA LABORATORY FOR AIDS VACCINE R&D$736,840
N01 · FY2017 · AI · contact PI
Evaluation of the Immunogenicity and Efficacy of a DNA Prime/Protein Boost Vaccine$715,267
N01 · FY2017 · AI · contact PI
COMPREHENSIVE RESOURCES FOR HIV MICROBICIDES AND BIOMEDICAL PREVENTION$394,121
N01 · FY2017 · AI · contact PI
Evaluation of Immune Responses to a Trimerically Stabilized gp120 Immunogen$368,553
N01 · FY2017 · AI · contact PI
SVEU - MAINTENANCE OF NONHUMAN PRIMATES$307,005
N01 · FY2017 · AI · contact PI
Conduct Study P193: Evaluation of Immune Responses after Priming with Newcastle Disease Virus and Boosting with Trimeric gp145 Proteins from Indian and African Clade C HIV-1 Isolates$129,321
N01 · FY2017 · AI · contact PI
SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY$2,166,265
N01 · FY2016 · AI · contact PI
IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS$1,576,546
N01 · FY2016 · AI · contact PI
IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS$1,369,907
N01 · FY2016 · AI · contact PI
IGF::OT::IGF QUALITY ASSURANCE/ QUALITY CONTROL (QA/QC)$738,015
N01 · FY2016 · AI · contact PI
NONHUMAN PRIMATE CORE QUANT IRAL RNA LABORATORY FOR AIDS VACCINE R&D$717,307
N01 · FY2016 · AI · contact PI
Conduct Study P193: Evaluation of Immune Responses after Priming with Newcastle Disease Virus and Boosting with Trimeric gp145 Proteins from Indian and African Clade C HIV-1 Isolates$445,044
N01 · FY2016 · AI · contact PI
SVEU - MAINTENANCE OF NONHUMAN PRIMATES$299,702
N01 · FY2016 · AI · contact PI
Conduct of Virus In Vivo Titration Study (P196): âIn Vivo SHIV Titration via Intrarectal Route in Indian-origin Rhesus Macaquesâ$129,943
N01 · FY2016 · AI · contact PI
TIER 2 SHIV-C CHALLENAGE OF NONHUMAN PRIMATES PREVIOUSLY PROTECTED FROM TIER 1 SHIV-C CHALLENGE$127,190
N01 · FY2016 · AI · contact PI
SVEU - Efficacy of HIV Clade C Vaccine Candidate with GP120 Boost$23,078
N01 · FY2016 · AI · contact PI
SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY$2,163,717
N01 · FY2015 · AI · contact PI
Conduct Study P193: Evaluation of Immune Responses after Priming with Newcastle Disease Virus and Boosting with Trimeric gp145 Proteins from Indian and African Clade C HIV-1 Isolates$867,569
N01 · FY2015 · AI · contact PI
NONHUMAN PRIMATE CORE QUANT IRAL RNA LABORATORY FOR AIDS VACCINE R&D$698,400
N01 · FY2015 · AI · contact PI
SVEU - MAINTENANCE OF NONHUMAN PRIMATES$438,924
N01 · FY2015 · AI · contact PI
SVEU - CONDUCT OF STUDIES IN NONHUMAN PRIMATES: REIMMUNIZATION AND CHALLENG$332,996
N01 · FY2015 · AI · contact PI
SVEU - MAINTENANCE OF NONHUMAN PRIMATES$259,157
N01 · FY2015 · AI · contact PI
Conduct of Virus In Vivo Titration Study (P196): âIn Vivo SHIV Titration via Intrarectal Route in Indian-origin Rhesus Macaquesâ$219,135
N01 · FY2015 · AI · contact PI
SVEU - Prime Boost Efficacy, Boosting Immunization, and Virus Challenge Studies$127,065
N01 · FY2015 · AI · contact PI
TIER 2 SHIV-C CHALLENAGE OF NONHUMAN PRIMATES PREVIOUSLY PROTECTED FROM TIER 1 SHIV-C CHALLENGE$110,840
N01 · FY2015 · AI · contact PI
PREPARATION OF SHIV VIRUS STOCK$93,756
N01 · FY2015 · AI · contact PI
SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY$2,069,231
N01 · FY2014 · AI · contact PI
NONHUMAN PRIMATE CORE QUANT IRAL RNA LABORATORY FOR AIDS VACCINE R&D$680,011
N01 · FY2014 · AI · contact PI
TIER 2 SHIV-C CHALLENAGE OF NONHUMAN PRIMATES PREVIOUSLY PROTECTED FROM TIER 1 SHIV-C CHALLENGE$449,958
N01 · FY2014 · AI · contact PI
SVEU - CONDUCT OF STUDIES IN NONHUMAN PRIMATES: REIMMUNIZATION AND CHALLENG$438,713
N01 · FY2014 · AI · contact PI
SVEU - Prime Boost Efficacy, Boosting Immunization, and Virus Challenge Studies$352,580
N01 · FY2014 · AI · contact PI
SVEU - MAINTENANCE OF NONHUMAN PRIMATES$285,645
N01 · FY2014 · AI · contact PI
SVEU - MAINTENANCE OF NONHUMAN PRIMATES$247,531
N01 · FY2014 · AI · contact PI
IN VIVO SHIV TITRATION VIS INTRARECTAL ROUTE IN INDIAN-ORIGIN REHESUS MACAQUES$242,453
N01 · FY2014 · AI · contact PI
PREPARATION OF SHIV VIRUS STOCK$90,032
N01 · FY2014 · AI · contact PI
NONHUMAN PRIMATE CORE QUANT IRAL RNA LABORATORY FOR AIDS VACCINE R&D$662,121
N01 · FY2013 · AI · contact PI
NONHUMAN PRIMATE CORE QUANT IRAL RNA LABORATORY FOR AIDS VACCINE R&D$931,497
N01 · FY2012 · AI · contact PI
NONHUMAN PRIMATE CORE QUANT IRAL RNA LABORATORY FOR AIDS VACCINE R&D$627,681
N01 · FY2011 · AI · contact PI